All Cancer articles
-
NewsIn vivo CAR T review charts path to off-the-shelf cellular therapy
A review from researchers at Naval Medical University and Shanghai Jiao Tong University examines how engineering CAR T cells directly inside the body could cut manufacturing complexity and expand patient access to cellular immunotherapy.
-
NewsVaccine adjuvant AS01 shown to induce trained immunity in monocytes
A preclinical study published in Myeloid Cells reports that AS01, a vaccine adjuvant system, can induce trained immunity in human monocytes and reduce tumour growth in selected mouse cancer models.
-
ArticleHow disease exposes hidden epitopes that AI models may miss
A protein can look very different in disease without a single change to its sequence. Measuring these structural changes could reveal drug targets invisible to genomic and expression data alone.
-
NewsMayo Clinic strategy restores CAR T targets on aggressive thyroid tumours
Mayo Clinic researchers have shown that approved thyroid cancer drugs can restore a key antigen on aggressive tumour cells, making them visible once more to CAR T cells and improving treatment outcomes in preclinical models.
-
News‘Plug-and-play’ CAR T platform enables post-infusion immune cell reprogramming
City of Hope researchers have developed a modular ‘plug-and-play’ CAR T-cell platform that enables post-infusion reprogramming of engineered immune cells, offering a potential solution to treatment resistance driven by tumour evolution.
-
NewsWhat SIRPα reveals about how breast cancer takes hold in the brain
Scientists at Wake Forest University School of Medicine have uncovered a previously unrecognised cancer-intrinsic role for SIRPα in triple-negative breast cancer, linking the cell-surface protein to mitochondrial fission, tumour-cell migration and suppression of the brain’s immune defences.
-
NewsBig Picture Bio raises £2.2m to develop AI cancer combination therapies
UK-based cancer drug discovery company Big Picture Bio has closed £2.2 million in funding to advance AI-designed combination therapies into laboratory validation, using a generative world model to map complex tumour biology across disease sites and patient subgroups.
-
NewsLiver cancer organoids used to screen 1,600 potential treatments
Researchers at the University of Basel have screened more than 1,600 compounds using a biobank of 35 hepatocellular carcinoma organoids, identifying drug combinations that show selective anti-tumour activity across biologically diverse liver cancers.
-
NewsSalk researchers uncover how interferons switch from anti- to pro-cancer
Researchers at the Salk Institute have identified a cellular pathway through which prolonged interferon exposure triggers mitochondrial dysfunction, PGE2 production and suppression of anti-tumour immunity – offering a potential strategy for overcoming immunotherapy resistance.
-
NewsWhole-genome sequencing delivers actionable biomarkers in 73 percent of cancer patients
A large real-world study demonstrates that whole-genome sequencing can identify actionable biomarkers in nearly three-quarters of solid cancer patients.
-
NewsPatient-derived tumour organoid biobank maps cancer gene dependencies
A biobank of 256 patient-derived tumour organoids, combined with genome-wide CRISPR–Cas9 screening, has produced a detailed map of cancer gene dependencies across five tumour types, revealing both shared vulnerabilities and mutation-specific targets with implications for precision oncology.
-
NewsNew LOX target discovery could help overcome chemotherapy-resistant breast cancer
A preclinical study has identified lysyl oxidase as an intracellular survival factor in triple-negative breast cancer, with researchers demonstrating that sequentially blocking LOX and a compensatory ferroptosis defence pathway significantly suppresses tumour growth without chemotherapy.
-
WebinarWhat it really takes to turn cancer discoveries into new therapies
Five leading cancer researchers from across genomics, proteomics, cell biology, chemical biology and gene therapy dig into what’s driving cancer drug discovery forward and what’s still holding progress back.
-
NewsReview challenges one-size-fits-all approach to OSCC drug delivery
A new review published in the European Journal of Pharmaceutics and Biopharmaceutics argues that no single local drug-delivery formulation will suit every oral squamous cell carcinoma tumour, urging researchers to anchor development in clinical and biological context from the outset.
-
NewsBRAF identified as novel target for neuropathic pain treatment
Researchers at MD Anderson Cancer Center have discovered that BRAF, a protein well known for its role in cancer, may also drive chronic pain following nerve injury – raising the prospect of repurposing approved cancer drugs as treatments for neuropathic pain.
-
NewsHER3-DXd and olaparib combination boosts lung cancer treatment responses
A new preclinical study finds that combining the antibody-drug conjugate HER3-DXd with PARP inhibitor olaparib significantly improves treatment responses in NSCLC models, including those harbouring EGFR and KRAS mutations, by overwhelming DNA repair capacity and activating innate immune signalling.
-
NewsFirst-in-class drug targets ‘undruggable’ MYC in blood cancers
A first-in-class experimental drug has demonstrated preclinical activity against treatment-resistant blood cancers by exploiting a newly identified vulnerability between MYC and GSPT1, offering a potential route to one of oncology’s most elusive targets.
-
Article600+ patient-derived cancer models expand the search for drug targets
Hundreds of new patient-derived cancer models could strengthen target validation, identify cancer vulnerabilities and provide more representative systems for preclinical drug discovery.
-
NewsIL-17 identified as potential immunotherapy biomarker in ovarian cancer
A new study has identified IL-17 as a potential biomarker for immunotherapy response in a small subset of clear cell ovarian cancer cases, offering a possible route to personalised treatment for a disease historically resistant to immune-based therapies.
-
NewsExhausted T cells escape tumours to drive lasting cancer immunity
A preclinical study has identified a subset of exhausted, LAG3-expressing T cells capable of migrating out of tumours to establish long-term immune memory, with potential implications for LAG3-targeting cancer immunotherapies.